Stock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection

Stock Track

Aug 11

Shares of Amphastar Pharmaceuticals (AMPH) surged 8.81% in pre-market trading on Monday following the announcement that the U.S. Food and Drug Administration (FDA) has approved the company's Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP. This generic drug is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.

The FDA approval covers single-dose vials in dosages of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, highlighting the company's commitment to developing complex generics and maintaining high regulatory standards. The company plans to launch the product in the third quarter of 2025.

This approval positions Amphastar to enter a lucrative market. The comparable product, Venofer®, has reported sales of approximately $513 million over the past year. Investors are likely optimistic about the potential revenue boost this new product could bring to Amphastar, driving the significant pre-market stock price increase. The company's ability to successfully navigate the FDA approval process for complex generics may also be viewed positively by the market, potentially indicating future growth opportunities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1140567448"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140567448\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140567448?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-11 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140567448","market":"hk","top_or_hot":-1,"title":"Stock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection","media":"Stock Track","content":"<p>Shares of Amphastar Pharmaceuticals (AMPH) surged 8.81% in pre-market trading on Monday following the announcement that the U.S. Food and Drug Administration (FDA) has approved the company's Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP. This generic drug is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.</p>\n\n<p>The FDA approval covers single-dose vials in dosages of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, highlighting the company's commitment to developing complex generics and maintaining high regulatory standards. The company plans to launch the product in the third quarter of 2025.</p>\n\n<p>This approval positions Amphastar to enter a lucrative market. The comparable product, Venofer®, has reported sales of approximately $513 million over the past year. Investors are likely optimistic about the potential revenue boost this new product could bring to Amphastar, driving the significant pre-market stock price increase. The company's ability to successfully navigate the FDA approval process for complex generics may also be viewed positively by the market, potentially indicating future growth opportunities.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-11 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Amphastar Pharmaceuticals (AMPH) surged 8.81% in pre-market trading on Monday following the announcement that the U.S. Food and Drug Administration (FDA) has approved the company's Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP. This generic drug is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.</p>\n\n<p>The FDA approval covers single-dose vials in dosages of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, highlighting the company's commitment to developing complex generics and maintaining high regulatory standards. The company plans to launch the product in the third quarter of 2025.</p>\n\n<p>This approval positions Amphastar to enter a lucrative market. The comparable product, Venofer®, has reported sales of approximately $513 million over the past year. Investors are likely optimistic about the potential revenue boost this new product could bring to Amphastar, driving the significant pre-market stock price increase. The company's ability to successfully navigate the FDA approval process for complex generics may also be viewed positively by the market, potentially indicating future growth opportunities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMPH","symbol_name":"Amphastar Pharmaceuticals","start_time":0,"source_url":"","article_id":"1140567448","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140567448","pubTimestamp":1754915080,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Amphastar Pharmaceuticals (AMPH) surged 8.81% in pre-market trading on Monday following the announcement that the U.S. Food and Drug Administration (FDA) has approved the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMPH":"Amphastar Pharmaceuticals"},"translate_title":"股票追踪|FDA批准仿制药蔗糖铁注射液Amphastar Pharmaceuticals盘前飙升8.81%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMPH":1},"content_text":"Shares of Amphastar Pharmaceuticals (AMPH) surged 8.81% in pre-market trading on Monday following the announcement that the U.S. Food and Drug Administration (FDA) has approved the company's Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP. This generic drug is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.\nThe FDA approval covers single-dose vials in dosages of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, highlighting the company's commitment to developing complex generics and maintaining high regulatory standards. The company plans to launch the product in the third quarter of 2025.\nThis approval positions Amphastar to enter a lucrative market. The comparable product, Venofer®, has reported sales of approximately $513 million over the past year. Investors are likely optimistic about the potential revenue boost this new product could bring to Amphastar, driving the significant pre-market stock price increase. The company's ability to successfully navigate the FDA approval process for complex generics may also be viewed positively by the market, potentially indicating future growth opportunities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}